Novel antiangiogenic therapies for renal cell cancer.
Gordon
Michael S
MS
Arizona Cancer Center-Greater Phoenix Area, University of Arizona College of Medicine, Scottsdale, Arizona 85258, USA. msgordon@u.arizona.edu
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000098:blood supply / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D007680:Kidney Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D061965:Matrix Metalloproteinase Inhibitors; D013792:Thalidomide / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D004791:Enzyme Inhibitors; D061965:Matrix Metalloproteinase Inhibitors; D042461:Vascular Endothelial Growth Factor A; D013792:Thalidomide